Sergio Quezada
Gründer bei ACHILLES THERAPEUTICS PLC
Vermögen: 288 901 $ am 30.04.2024
Aktive Positionen von Sergio Quezada
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ACHILLES THERAPEUTICS PLC | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2020 | - |
| Gründer | 01.11.2020 | - | |
| University College London | Corporate Officer/Principal | 01.01.2011 | - |
Karriereverlauf von Sergio Quezada
Ehemalige bekannte Positionen von Sergio Quezada
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Gründer | 01.05.2016 | - |
Ausbildung von Sergio Quezada
| Dartmouth Medical School | Doctorate Degree |
| Pontificia Universidad Católica de Chile | Undergraduate Degree |
Statistik
International
| Vereinigtes Königreich | 4 |
| Vereinigte Staaten | 2 |
| Chile | 2 |
Operativ
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
 | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
- Börse
- Insiders
- Sergio Quezada
- Erfahrung
